Summary
Carcinoembryonic Antigen (CEA) is a protein that can be raised in several cancers, most notably colorectal (bowel) cancer. CEA is used mainly to monitor people who already have a cancer diagnosis — tracking response to treatment and detecting recurrence — rather than to screen healthy individuals, because it can be raised in many non-cancerous conditions and is not specific.
CEA is a protein normally produced during fetal development, with low levels in healthy adults. It can rise in colorectal, pancreatic, gastric, lung, breast, and other cancers, but also in benign conditions such as smoking, inflammatory bowel disease, liver disease, and infections.
Because of this lack of specificity, CEA is not a screening test. Its main value is in monitoring known cancers: a baseline is measured at diagnosis, and serial levels track treatment response. A rising CEA after treatment can be an early sign of recurrence, often before imaging changes.
CEA is interpreted alongside imaging and the clinical picture. Smokers tend to have higher baseline levels, which is taken into account.
What It Is
CEA is a glycoprotein cell-adhesion molecule of the immunoglobulin superfamily, normally expressed in fetal gut tissue and at low levels in adult epithelial cells. Malignant transformation, particularly of glandular epithelium, increases CEA expression and shedding into the blood.
CEA lacks the specificity needed for screening: it is elevated in several malignancies and in numerous benign conditions. Its established role is in the surveillance of colorectal cancer — guidelines recommend serial CEA monitoring after curative treatment to detect recurrence early.
Reference ranges: approximately < 3 ng/mL in non-smokers and < 5 ng/mL in smokers, varying by laboratory. The trend over time is generally more informative than a single value.
Functions
Cancer treatment monitoring
Tracks response to treatment in colorectal and other cancers — falling levels suggest response.
Recurrence detection
A rising CEA after treatment can be an early sign of cancer recurrence, sometimes before imaging changes.
Baseline and prognosis
A high CEA at diagnosis can indicate more advanced disease and helps establish a baseline for monitoring.
Trend tracking
Serial measurements over time are more informative than any single result.
Reference Ranges
Carcinoembryonic Antigen (CEA)
Measured in ng/mL| Status | Range (ng/mL) | Range (μg/L) | What it means |
|---|---|---|---|
| Normal (non-smoker) | < 3 | Within the normal range for non-smokers. | |
| Normal (smoker) | 3–5 | Often normal in smokers; mild elevation is commonly benign. | |
| Elevated | > 5 | Elevated — interpret with clinical context; significant in monitoring known cancer. |
CEA is not a screening test. Reference ranges differ for smokers and non-smokers and between laboratories. Many benign conditions raise CEA. The trend over time, in the context of a known diagnosis, is the key to interpretation.
Symptoms of Imbalance
CEA itself causes no symptoms; an elevated level reflects an underlying cancerous or benign condition.
- A normal CEA is reassuring but does not exclude cancer
- No symptoms from a low CEA
- Symptoms depend on the underlying cause
- Change in bowel habit, blood in stool, weight loss (colorectal cancer)
- Often no symptoms with benign causes
- Symptoms of the relevant cancer if malignant
Causes of Imbalance
- Normal in healthy adults
- Effective cancer treatment (falling CEA)
- Colorectal cancer (and other cancers: pancreatic, gastric, lung, breast)
- Smoking
- Inflammatory bowel disease
- Liver disease and cirrhosis
- Pancreatitis
- Benign lung and gastrointestinal conditions
FAQs
No. CEA is not suitable for screening healthy people because it is not specific — it can be raised in several cancers and in many benign conditions such as smoking, inflammatory bowel disease, and liver disease, while also being normal in some people with cancer. Its established role is in monitoring people who already have a cancer diagnosis, particularly colorectal cancer.
Smoking raises baseline CEA levels, so smokers generally have a higher normal range (up to around 5 ng/mL) than non-smokers (up to around 3 ng/mL). This is a benign effect and is taken into account when interpreting results. It is one of the reasons CEA is not used for screening and is best interpreted as a trend over time rather than a single value.
In someone treated for colorectal cancer, a steadily rising CEA can be an early sign of recurrence, sometimes appearing before changes are visible on scans. This is why CEA is monitored at intervals after treatment. A rising trend prompts further investigation with imaging. A single mildly elevated value, however, is interpreted cautiously and usually repeated.
A single mildly elevated CEA in an otherwise well person is most often due to a benign cause, such as smoking, a gastrointestinal or liver condition, or inflammation. Because CEA is non-specific, it is interpreted alongside symptoms, other tests, and the overall clinical picture. Persistent or rising levels, or elevation in someone with relevant symptoms, would prompt further assessment.
References
- Locker GY, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327. View source
- Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47(4):624–630. View source
- Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005;23(4):338–351. View source